Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Lung cancer illustration

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

ADT use associated with Alzheimer’s disease, dementia

Dementia_illustration

Older prostate cancer patients who use androgen deprivation therapy may be at increased risk for developing Alzheimer’s disease or dementia, findings indicate.

Click through for comments from study author Ravishankar Jayadevappa and independent expert David Robinson.

Expansion of USPSTF lung screening criteria warranted

Doctor looking at CT lung scans

Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Clear vial_injection 2

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

Latest headlines

23-07-2019 | Bladder cancer | News

Nomogram-predicted recurrence risk may aid adjuvant chemotherapy stratification in MIBC

Muscle-invasive bladder cancer patients with a nomogram-derived 1-year recurrence probability of at least 40% are likely to benefit from adjuvant chemotherapy, suggests a retrospective study.

22-07-2019 | Non-small cell lung cancer | News

Local ablative therapy–pembrolizumab benefit suggested for metastatic NSCLC

Data from two phase II studies published in JAMA Oncology lend support to the sequential use of local ablative therapy and PD-1 blockade in patients with metastatic non-small-cell lung cancer.

19-07-2019 | Bladder cancer | News

NCCN releases guidance for bladder cancer patients

The National Comprehensive Cancer Network has issued patient-oriented guidelines to help individuals with bladder cancer better understand and manage their condition.

In depth

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

28-01-2019 | Immunotherapy | At a glance | Article

Gut microbiota and immunotherapy response: A round-up of the trials

A round-up of the key studies – all published in Science – that have investigated the association between the gut microbiome and response to immune checkpoint inhibitors.

Image Credits